Things categorized as 'M&A'
CV Tells Astellas to Shove It: Looks to Gilead
All this talk by Astellas about taking over the board of directors and taking the decisision to the shareholders seems it may have been in ...
Mega-mergers Are Not Good For Business
There's an article this morning on Bloomberg insinuating that the Pfizer/Wyeth, Genentech/Roche and now Merck/Schering-Plough mergers have placed pressure on the remaining members of ...
Merck to Buy Schering-Plough for $41.1 Billion Cash and Stock Deal
Not to be outdone by Pfizer / Wyeth, Merck and Schering-Plough announced that their Boards of Directors have unanimously approved a merger. Schering has ...
Proteon Therapeutics Has A Big Day
Proteon Therapeutics announced it has successfully completed a $38 million Series B equity financing, started a Phase 1/2 clinical trial with its lead product, PRT-201, ...
They Weren’t Bluffing: Astellas Lauches Tender Offer for CV Therapeutics
Astellas announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all outstanding shares of common stock of CV Therapeutics ...
GSK Not Joining Pharma-mergerfest-a-palooza ‘09
With Sanofi Aventis circling the wagons (i.e., pulling the charge card out of its European manpurse) for a major deal and just one ...
Roche makes lowered, hostile offer for Genentech (AP)
Roche made a fresh bid to buy Genentech this morning by offering $86.50 per share -- $2.50 less than its previous offer. Hostile bids are always ...
Pfizer-Wyeth
Image via Wikipedia In my last post, I gave five reason for Pfizer not to buy Wyeth and said I would be astonished ...
Roche Pays Pittance for Memory Pharmaceuticals
Some say the economy is terrible. I'm not going to disagree though, it is a wonderful time for a bargain hunting company with a wad ...
J&J Nabs Omrix for $438M
Johnson & Johnson and Omrix Biopharmaceuticals, a biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be ...
BBM Offers to Acquire YM BioSciences for $29M
Talk about a tough market, according to a recent report, half of all biotech's with a market cap under $200M are trading for less than ...
GlaxoSmithKline to acquires Genelabs Technologies for $57M
I'm a huge fan of early stage deals with lots of upside and a cost under $75M. GlaxoSmithKline, looking to shore up their hepatitis C pipeline, ...
No Rumors For You. Come Back. One Year
Cutting costs or adding non-core business assets? Either, the rumor mongers who keep this Pfizer/Bayer rumor alive lack common sense or Pfizer does. Read More →
One Man’s Trash: Novartis Buys Nektar’s Pulmonary Division for $115M
After one of the most spectacular failures in pharmaceutical marketing history (Pfizer/Nektar's Exubera; inhaled insulin), Read More →
The Swami Was Right: Lilly Buys ImClone
The WSJ is reporting this morning Eli Lilly has inked a $6.5B deal to buy ImClone. I guess the Swami was right.